Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Minghui Starts Clinical Trials for Two Novel ADCs Aimed at Solid Tumor Cancers

publication date: Jun 21, 2023

Shanghai Minghui Pharma has dosed the first patients in two Phase 1 clinical studies of two antibody drug candidates that target TROP-2 and B7-H3 for advanced/metastatic solid tumor cancers. The two candidates, MHB036C and MHB088C, contain a potent topoisomerase (TOPO) 1 inhibitor linked with antigens via a cleavable linker. Minghui believes its novel payload increases the therapeutic potency of its ADCs, especially against cancer cells with lower antigen expression. The two trials will determine the maximum tolerated dose, the recommended Phase II dose, and they will assess the pharmacokinetics and preliminary efficacy of the candidates. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital